These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Diagnostic Value and Challenges of BRAF V600E Molecular Testing and Thyroid Fine-Needle Aspiration Cytology: A Retrospective Study from a Tertiary Institution in Southern Hunan Province, China. Lan Z, Yang F, Zhang J, Lan Y, Li H, He R. Acta Cytol; 2023; 67(6):629-638. PubMed ID: 37708867 [Abstract] [Full Text] [Related]
7. The Risk Stratification of Papillary Thyroid Cancer With Bethesda Category III (Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance) by Thyroid Fine-Needle Aspiration Could Be Assisted by Tumor Size for Precision Treatment. Zha X, Miao Z, Huang X, Wang X, Xie R, Jin J, Zou D, Yang P, Huang Y. Front Endocrinol (Lausanne); 2022; 13():822423. PubMed ID: 35197932 [Abstract] [Full Text] [Related]
10. BRAF V600E mutation and microRNAs are helpful in distinguishing papillary thyroid malignant lesions: Tissues and fine needle aspiration cytology cases. Zarkesh M, Zadeh-Vakili A, Akbarzadeh M, Nozhat Z, Fanaei SA, Hedayati M, Azizi F. Life Sci; 2019 Apr 15; 223():166-173. PubMed ID: 30890403 [Abstract] [Full Text] [Related]
12. Correlation between US-FNAC with BRAF V600E Mutation Analysis and Central Neck Lymph Node Metastasis in cN0 Papillary Thyroid Cancer. Li R, Hao J, Zhu Z, Qiao X, Wang L, Zhou Z. Biomed Res Int; 2021 Apr 15; 2021():9937742. PubMed ID: 34307677 [Abstract] [Full Text] [Related]
13. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma. Pelizzo MR, Dobrinja C, Casal Ide E, Zane M, Lora O, Toniato A, Mian C, Barollo S, Izuzquiza M, Guerrini J, De Manzini N, Merante Boschin I, Rubello D. Biomed Pharmacother; 2014 May 15; 68(4):413-7. PubMed ID: 24721322 [Abstract] [Full Text] [Related]